APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
The partnership will capitalize on the combined capabilities of the two organizations
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Fully equipped labs with 75-member team set-up and made operational in <100 days
Subscribe To Our Newsletter & Stay Updated
